Please login to the form below
CEVEC and Catalent partner on cell lines
CEVEC Pharmaceuticals and Catalent Pharma Solutions have launched a joint commercial cell line development service for pharma and biotech customers worldwide
CEVEC Pharmaceuticals and Catalent Pharma Solutions have launched a joint commercial cell line development service for pharma and biotech customers worldwide.
The offering combines the benefits of CEVEC's human cell line, CAP-Technology, with Catalent's unique GPEx (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.
Wolfgang Kintzel, managing director of CEVEC, said: "The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line."
Share
Related Hub content
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
